Myelodysplasia Clinical Trial
Official title:
A Pilot Study of Clofarabine Pre-conditioning Prior to Full or Reduced Intensity Allogeneic Transplantation in the Treatment of High Risk Acute Myeloid Leukaemia and Myelodysplasia.
This study has been designed to investigate the safety and feasibility of using a chemotherapy drug, Clofarabine, to reduce the disease burden before a donor transplant, in patients with high risk Acute Myeloid Leukaemia or Myelodysplasia (MDS). In this study Clofarabine chemotherapy will be given a few days before a reduced or full intensity donor stem cell transplant and without waiting for normal blood counts to recover. It is hoped that this approach may improve the outcome for patients with high risk AML and MDS after their transplant.
This is a pilot study. Twenty patients in total will be treated in two cohorts of 10 patients
each.
- Cohort One: Patients suitable for full intensity conditioning will receive Clofarabine
pre-conditioning followed by a Cyclophosphamide and Total Body Irradiation conditioned
allogeneic stem cell transplant.
- Cohort Two: Patients not suitable for a full intensity TBI-based transplant due to age
or co-morbidity will receive Clofarabine pre-conditioning followed by a reduced
intensity allogeneic stem cell transplant using Fludarabine, intravenous Busulphan and
Campath 1H.
The cohorts will be recruited concurrently. It is anticipated that recruitment of the 20
subjects will be achieved in 18 months to two years.
The study will be conducted at a single centre (Southampton, UK) in the first instance.
This design allows the use of a full intensity, TBI-based transplant conditioning schedule,
for younger patients able to tolerate this approach but also the use of a reduced intensity
transplant conditioning schedule in older or less fit patients who may still benefit from
pre-conditioning with Clofarabine followed by an allogeneic stem cell transplant. This
design, therefore, does not restrict potential recruitment to the study on age or performance
status alone (within the limits set by ability to tolerate intensive chemotherapy and a
transplant procedure).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Recruiting |
NCT02323867 -
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
|
Phase 2 | |
| Completed |
NCT01933035 -
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
|
N/A | |
| Completed |
NCT00990587 -
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
|
Phase 1 | |
| Terminated |
NCT00594308 -
In-Vivo Activated T-Cell Depletion to Prevent GVHD
|
N/A | |
| Terminated |
NCT00514722 -
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
|
N/A | |
| Completed |
NCT00513175 -
Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
|
N/A | |
| Recruiting |
NCT04202835 -
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
|
Phase 2 | |
| Completed |
NCT03613727 -
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
|
Phase 2 | |
| Completed |
NCT00580242 -
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia
|
Phase 1 | |
| Completed |
NCT00506402 -
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00516152 -
Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
|
Phase 2 | |
| Completed |
NCT01956799 -
Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
|
||
| Terminated |
NCT00109538 -
Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)
|
Phase 3 | |
| Completed |
NCT00578942 -
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
|
Phase 2 | |
| Active, not recruiting |
NCT00145626 -
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
|
Phase 2 | |
| Active, not recruiting |
NCT00899223 -
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
|
||
| Recruiting |
NCT04800458 -
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
|
N/A | |
| Recruiting |
NCT05735717 -
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
|
Phase 2 |